The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?
This lecture was part of a CME accredited symposium: 'A novel approach for high CV risk patients with diabetes: The potential of epigenetics' held at ESC 2016 in Rome
Video navigation menu
- The cardiovascular burden of diabetes 00:17
- Reducing CV risk in T2DM may need a multifactorial approach 03:04
- Perturbed vasculature as a target for therapy 03:36
- Targeting HDL function/HDL-C efflux to reduce CV events 05:46
- Other potential pathways as treatment target in patients with diabetes 06:22
- Reduction of CV risk by apabetalone, an inhibitor of BET-proteins 06:58
- Summary 07:46
The educational objectives of this symposium were:
- To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
- To understand the origin of the high residual cardiovascular risk in patients with diabetes & ACS
- To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD
- To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management.
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).
Prof. Kausik Kumar Ray is currently Professor of Public Health, Department of Public Health and Primary Care, School of Public Health, Imperial College London
Supported by an unrestricted educational grant from Resverlogix